Skip to main content
SpringerLink
Log in

Antifungal prophylaxis and therapy: controversies and emerging issues

  • Chapter
Infectious Complications in Transplant Recipients

Part of the book series: Perspectives on Critical Care Infectious Diseases ((CCID,volume 1))

  • 83 Accesses

Abstract

Fungal infections in solid organ transplant recipients remain a substantial cause of morbidity and mortality and can occur in all types of transplant recipients. Fungal species and infection type differ, between the organ transplanted and geographic residence (1-3). The reported prevalence range from around 5% in kidney recipients, to as high as 53% in small bowel transplant recipients (4-7). The principle fungal patogen found among transplant recipients are species ofCandida Aspergillus andCryptococcos neoformans. Mortality is substantial, with a maximum mortality rate reported to range between 70% for candidosis and up to 100% in case of aspergillosis (2). The occurrence and management of fungal infections in these patients depends on factors, such as host’s predisposition, lack of reliable diagnostic methods and a therapeutic arsenal associated with toxicity, lack of coverage, drug-drug interactions, side-effects or expensive treatment..

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rubin HR. Infection in the organ transplant recipient. In: Rubin RH, Young LS (eds)Clinical Approach to Infection in the Compromised Host.3rd edn. Plenum Medical Book Co, New York, 1994, pp 629–705.

    Chapter  Google Scholar 

  2. Hadley S, Karchmer AW. Fungal infections in solid organ transplant recipients. Infect Dis Clin N Am 1995;4: 1045–1074.

    Google Scholar 

  3. Hibberd PL, Rubin RH. Clinical aspects of fungal infections in organ transplant recipients. Clin Infect Dis 19 (suppl 1): S33–S40.

    Google Scholar 

  4. Rifkind D, Marchcioro TL, Schneck SA, et al. Systemic fungal infections complicating renal transplantation and immunosuppressive therapy. Am J Med 1967; 43: 28.

    Article  PubMed  CAS  Google Scholar 

  5. Baumgartner WA, Peitz BA, Oyer PE et al. Cardiac homotransplantation. Curr Probl Suri 1979;16:1–61.

    Article  CAS  Google Scholar 

  6. Fishman JA, Rubin RG. Fungal infections in the organ transplant recipient: Challenges and oppurtunities. In: Vincent JL. ed.Yearbook of Intensive Care and Emergency Medicine.Berlin, Springer-Verlag, 1996; 555–566.

    Chapter  Google Scholar 

  7. Wajszczuk CP, Dummer JS, HO M, et al. Fungal infections in liver transplant recipients. Transplantation 1985;40: 347–353.

    Article  PubMed  CAS  Google Scholar 

  8. Dummer JS, Hardy A, Poorsatter A et al. Early infections in kidney, heart, and liver transplant recipientson cyclosporine. Transplantation 1983;36:259–267.

    Article  PubMed  CAS  Google Scholar 

  9. Kusne S, Abu-Elmagd K, Hutson W, et al. Invasive fungal infections after adult small bowel transplantation (SBTX) Abstract no: 034 At: 5th International Symposium on Small Intestinal Transplantation, Cambridge, UK, July 31-August 2, 1997.

    Google Scholar 

  10. Masur H, Cheigh JS, Stubenbord WT. Infection following renal transplantation: a changing pattern. Rew Infect Dis 1982;4:1208–1219.

    Article  CAS  Google Scholar 

  11. Gustafson TL, Schaffner W, Lavely GB, et al. Invasive aspergillosis in renal transplant recipients: Correlation with corticosteroid therapy. J Infect Dis 1983; 148: 220–238.

    Google Scholar 

  12. Chugh KS, Sakhuja V, Jain S, et al. High mortality in systemic fungal infections following renal transplantation in third-world countries. Nephrol Dial Transplant 1993; 8:168–172.

    PubMed  CAS  Google Scholar 

  13. Petterson PK, Ferguson R, Fryd DS et al. Infectious diseases in hospittalized renal transplant recipients: A prospective study of a complex and evolving problem. Medicine 1982; 61: 360372.

    Google Scholar 

  14. Gallis HA, Berman RA, Cate TR, et al. Fungal infections following renal transplantation. Arch Intern Med 1975; 135: 1163–1172.

    Article  PubMed  CAS  Google Scholar 

  15. Weiland D, Ferguson RM, Peterson PK, et al. Aspergillosis in 25 renal transplant patients: Epidemiology, clinical presentation, diagnosis and management. Ann Surg 1983; 198: 622629.

    Google Scholar 

  16. Gallis HA, Berman RA, Cate TR, et al. Fungal infection following renal transplantation. Arch Intern Med1975;135: 1163–1172.

    Article  PubMed  Google Scholar 

  17. Murphy JF, McDonald FD, Dawson M, Reite A, Turcotte J, Fekey FR Jr. Factors affecting the frequency of infection in renal transplant recipients. Arch Intern Med1976;136: 670–67

    Article  PubMed  Google Scholar 

  18. Tollemar J. Fungal Infections in solid organ transplant recipients inTransplant Infections, eds. Bowden, Ljungman and Paya. Lipppincott-Raven, Philadelphia 1998; 339–350.

    Google Scholar 

  19. Odds FC.Candida and candidosis. A review and bibliography.2 nd ed. London: Bailliere Tindall, 1988.

    Google Scholar 

  20. Hay RJ. Dimorphism and Candidosis: Clinical and Therapeutic implications. Diagnosis and treatment of Mycoses. In Dimorphic fungi in Biology and medicine, eds. Vanden Bossche, Odds and Kerridge, New York, Plenum Press 1993;373–379.

    Google Scholar 

  21. Piper JP,Rinaldi MG, Winn RICandida parapsilosis: an emerging problem. Infecttious Diseases Newsletter 1988; 7: 49–52.

    Article  Google Scholar 

  22. Wingard JR, Metz WG, Rinaldi MGet al.Increase in Candida Krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Eng J Med 1991; 325, 1274–1277.

    Article  CAS  Google Scholar 

  23. Wingard JR, Merz WG, Rinaldi MGet al.Association of Torulopsis glabratainfections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother, 1993; 37, 1847–1849.

    Article  PubMed  CAS  Google Scholar 

  24. Dupont B. Clinical manifestations and management of candidosis in the compromised patient. In: Warnock DW, Richardson MD (eds)Fungal infection in teh compromised patient.2nd eds. John Wiley &sons Ltd, Chichester, pp 56–83.

    Google Scholar 

  25. Fisher JF, Chew WH, Shadomy S, et al. Urinary tract infections due toCandida albicans.Rev Infect Dis 1982; 4: 1107–1118.

    Article  PubMed  CAS  Google Scholar 

  26. Rubin RH. Infectious disease complications of renal transplantation. Kidney Int 1993; 44: 221–236.

    Article  PubMed  CAS  Google Scholar 

  27. Zeluff JZ. Fungal pneumonia in transplant recipients.Seminars in Respiratory Infections1990; 1: 80–89.

    Google Scholar 

  28. Paya CV, Hermans PE, Washington JA, et al. Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clin proc 1989; 64: 555–564.

    Article  PubMed  CAS  Google Scholar 

  29. Gomez-Mateos JM, Porto AS, Parra DM, Balbutin AR, Serrano AL, Lugne JA. Disseminated candidiasis and gangrenous cholecyctitis due to Candida spp.xJournal of Infectious Diseases1988; 158: 653–655.

    Google Scholar 

  30. Brooks RG, Hofflin JM, Jamieson SW, Stinson EB, Remmington JS. Infectious complications in heart-lung transplant recipients. Am J Med 1985; 79: 412–422.

    Article  PubMed  CAS  Google Scholar 

  31. Eras P, Golstein MJ, Sherlock P. Candida infection of the gastrointestinal tract.Medicine1972; 51: 367–379.

    Article  PubMed  CAS  Google Scholar 

  32. Bodey GP, Vartivarian S. Aspergillosis. Eur J Clin Microbiol Infect Dis 1989; 8: 413–437.

    Article  Google Scholar 

  33. Meunier F. Prevention of Mycoses in Immunocompromised Patients. Rev Infect Dis 1987;2:408–416.

    Article  Google Scholar 

  34. Rinaldi MG. Invasive aspergillosis. Rew of Infecti Dis 1983; 5: 1061–1077.

    Article  CAS  Google Scholar 

  35. Cohen J. Clinical manifestation and management of aspergillosis in the

    Google Scholar 

  36. compromised patient. In: Warnock DW, Richardson MD (eds)Fungal infection in teh compromised patient.2nd eds. John Wiley &sons Ltd, Chichester, pp 118–152.

    Google Scholar 

  37. Kramer MR, Denning DW, Marshall SE, et al. Ulcerative tracheobronchitis after lung transplantation: a new form of invasive aspergillosis. Am Rew Respir Dis 1991; 144: 552–556.

    Article  CAS  Google Scholar 

  38. Singh N, Arnow PM, Bonham A, et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997; 64: 716–720.

    Article  PubMed  CAS  Google Scholar 

  39. Hay RJ. Clinical manifestations and management of cryptococcosis in the compromised patient. In: Warnock DW, Richardson MD (eds)Fungal infection in teh compromised patient.2nd eds. John Wiley & sons Ltd, Chichester, pp 85–116

    Google Scholar 

  40. Wheat LJ, Fungal infection in the Immunocompromised Host. In: Rubin RH, Young LS (eds)Clinical Approach to Infection in the Compromised Host.3rd edn. Plenum Medical Book Co, New York, 1994, pp 211–237.

    Chapter  Google Scholar 

  41. Wolfson JS, Sober AJ, Rubin RH. Dermatologic manifestations of infections in immunocompromised patients.Medicine1985; 64: 115–133.

    Article  PubMed  CAS  Google Scholar 

  42. Schröter GPJ, Temple DR, Husberg BS, et al. Cryptococcosis after renal transplantation: Report of ten cases.Surgery1976; 79: 268–277.

    PubMed  Google Scholar 

  43. Skahan KJ, Wong B, Armstrong D. Clinical manifestation and management of mucormycosis in the compromised patient. In: Wamock DW, Richardson MD (eds)Fungal infection in teh compromised patient.2nd eds. John Wiley &sons Ltd, Chichester, pp 154–190.

    Google Scholar 

  44. Hammer GS, Bottone EJ, Hirschman SZ. Mucormycosis in a transplant recipient.American Journal of Clinical Pathology1975; 64: 389–398.

    PubMed  CAS  Google Scholar 

  45. Fisher J, Tuazon CU, Geelhoed GW. Mucormycosis in transplant patients.American Surgeon1980; 46: 315–322.

    PubMed  CAS  Google Scholar 

  46. Morduchowicz G, Pitlik SD, Shapira Z, Shmueli AY, Djalovski S, Rosenfeld JB. Infection in renal transplant recipients in Israel.Israel Journal of Medical Sciences1985; 21: 791–797.

    PubMed  CAS  Google Scholar 

  47. Cohen IM, Galgiani JN, Potter D, Ogden DA. Coccidioidomycosis in renal replacement therapy. Arch Int Med 1982; 489–494.

    Google Scholar 

  48. Calhoun DL, Galgiani JN, Zvkoski C, et al. Coccidiodomycosis in recent renal or cardiac transplant recipients, In Einstein HE, Catanzaro A (eds):Proceedings of teh 4th International Conference on coccidioidomycosis.Washington, DC, National Foundation for Infectious Diseases 1985;2 312–318.

    Google Scholar 

  49. Wheat LJ, Smith El, Sathapatyavongs B et al. istoplasmosis in renal allograft recipients: Two large urban outbreaks.Arch Intern Med1983; 143: 703–707.

    Article  PubMed  CAS  Google Scholar 

  50. Warnock DW, Johnson EM.1998 Clinical manifestation and management of hyalohyphomycosis, phaeohyphomycosis and other uncommon forms of fungal infection in the compromised patient. In: Warnock DW, Richardson MD (eds)Fungal infection in teh compromised patient.2nd eds. John Wiley &sons Ltd, Chichester, pp 247–310.

    Google Scholar 

  51. Rubin RH, Tolkoff-Rubin NE. Antimicrobial strategies in the care of organ transplant recipients, Antimicrob Agents Chemother 1993; 37: 619–624.

    Article  PubMed  CAS  Google Scholar 

  52. Warnock DW. Amphotericin B: an introduction. J Antimicrob Chemother 1991; 28 Suppl. B: 27–38.

    Article  Google Scholar 

  53. Shulman H, Striker G, Deeg HJ, et al. Nephrotoxicity of cyclosporine A after allogeneic marrow transplantation. New Engl J Med 1981;305:1392–1395.

    Article  PubMed  CAS  Google Scholar 

  54. Francis P, Walsh TJ. Evolving role of flucytocin in immunocompromised patients: new insights into safety, pharmacokinetics, anti antifungal therapy. Clin Infect Dis 1992; 15: 1003–1018.

    Article  PubMed  CAS  Google Scholar 

  55. Tollemar 1, Svahn BM, Remberger M, Ringde’n O. Invasive fungal infections in solid orgaan transplant recipients, incidence and treatment efficacy of liposomal amphotericin B treatment (AmBisome). Abstract no: 392 At: 8 th Congress of the European Society for Organ Transplantation, Budapest, Hungary, September 2–6, 1997.

    Google Scholar 

  56. Ringdén O, Ekelöf Andstrom E, Remberger M, DahllOf G, Svahn B-M and Tollemar J. Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation. Pediatr Transplantation 1997: 1; 124–129.

    Google Scholar 

  57. Janknegt R, de Marie S, Baaker-Woudenberg IAJM et al. Liposomal and Lipid Formulations of Amphotericin B Clinical Pharmacokinetics. Clin Parmacokinet 1992; 23(4): 279–291.

    Article  CAS  Google Scholar 

  58. White MH, Anaissie EJ, Kusne S et al. Amphotericin B colloidal dispertion vs. Amphotericin B as therapy for invasive Aspergillosis. Clinical Infectious Diseases 1997; 24: 635–642.

    PubMed  CAS  Google Scholar 

  59. Wingard JR. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplantation 1997; 19: 343–347.

    Article  PubMed  CAS  Google Scholar 

  60. Tollemar 1, Ringde’n O. Lipid Formulations of Amphotericin B: Less Toxicity But at What Economic Cost ?. Drug Safety 1995; 13 (4): 207–218.

    Article  Google Scholar 

  61. Noskin G, A, Pietrelli L. Coffey G.et al. Amphotericin B Colloidal dispertion for treatment of candidemia in immunocompromised patients. Clin Infect Dis 1998; 26: 461–467.

    Article  PubMed  CAS  Google Scholar 

  62. Walsh Ti, Hiemenz J. W, Seibel N. I, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383–1396.

    Article  Google Scholar 

  63. Bodey GP. Azole antifungal agents. Clin Infect Dis 1992; 14 Suppl 1: S161–169.

    Article  CAS  Google Scholar 

  64. Sugar AM, Saunders C, Idelson BA, et al. Interaction of fluconazole and cyclosporine. Ann Intern Med 1989; 110: 844.

    Article  PubMed  CAS  Google Scholar 

  65. Kwan JTC, Foxall PJD, Davidson DCG, et al. Interaction of cyclosporine and itraconazole. Lancet 1987; 2: 282.

    Article  PubMed  CAS  Google Scholar 

  66. Manez R, Martin M, Raman V, et al. Fluconazole therapy in transplant recipients recieving FK506. Transplantation 1994; 57 (Brief communication): 1521–1535.

    PubMed  CAS  Google Scholar 

  67. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325–1330.

    Article  PubMed  CAS  Google Scholar 

  68. Nanas JN, Saraglou G, Anastasiou-Nana M.I, et al Itraconazole for the treatment of pulmonary aspergillosis in heart transplant recipients. Clin Transplan 1998; 12: 30–34.

    CAS  Google Scholar 

  69. Edwards JE Jr, Bodey GP, Bowden RA, et al. International confecrence for the development of a consensus on the management and prevention of severe candida) infections. Clin Infect Dis 1997;25:43–59.

    Article  PubMed  Google Scholar 

  70. Conti DJ, Tolkoff-Rubin NE, Baker GP, et al. xSuccessful treatment of invasive fungal infection with fluconazole in organ transplant recipients.Transplantation 1989; 48: 692–694.

    CAS  Google Scholar 

  71. Bren A, Kandus A, Lindic J, Vari J. x Fluconazole in the treatment of fungal infections in kidney-transplanted patients.Transplantation Proceedings 1992; 24: 2765–2766.

    CAS  Google Scholar 

  72. Durand F, Bernau J, Dupont B, Sauvanet A, Belghiti J, Degott C, Benhamou JP.Aspergillusintraabdominal abcess after liver transplantation successfully treated with itraconazole. Transplantation 1992; 54: 734–735.

    Article  PubMed  CAS  Google Scholar 

  73. Dismukes WE, Cloud G, Gallis HA, et al. Treatment of cryptococcal meningitis with combination amphotericin b and flucytocin for four as compared with six weeks. N Engl J Med 1987;317: 334–341.

    Article  PubMed  CAS  Google Scholar 

  74. Tollemar J, Prophylaxis against fungal infections in transplant recipients. BioDrugs 1999; 11: 309–318.

    Article  PubMed  CAS  Google Scholar 

  75. Briegel J, Forst H, Spill B, et al Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 1995; 14: 375–382-

    Article  PubMed  Google Scholar 

  76. Chang F.Y, Singh N, Gayowski T, et al. Trombocytopenia in liver transplant recipients: predictor on fungal infections, and role of endougenous thrombopoietin. Transplantation 2000; 69: 70–75.

    Article  PubMed  CAS  Google Scholar 

  77. Tollemar J, Höckerstedt K, Ericzon BG, Jalanko H, Ringdén O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo controlled study. Transplantation 1995; 59: 1:45–50.

    Article  PubMed  CAS  Google Scholar 

  78. Tollemar J, Höckerstedt K, Ericzon B-G, Jalanko H, Ringdén O. Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: Longterm results of a randomized, placebo controlled trial. Transplant. Proc 1995; 27: 11951198.

    Google Scholar 

  79. Lumbreras C, Cuervas-Mons V, Jara P et al Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J of Infect Dis 1996; 174: 583–588.

    Article  CAS  Google Scholar 

  80. Winston D. J, Pakrasi A, Busuttil R.W. Propylactic fluconazole in liver transplant recipients, a randomized, double-blind, placebo-controlled trial. Annals of Internal Med 1999; 131: 729737.

    Google Scholar 

  81. Decruyenaere J, Colardyn F, Vogelaers D. Combined use of fluconazole and selective digestive decontamination in the prevention of fungal infection after adult liver transplantation. Transplantation Proceedings 1995; 27: 3515–2516.

    PubMed  CAS  Google Scholar 

  82. Colby W.D, Sharpe MD, Ghent C.N, et al Efficacy of Itraconazole prophylaxis against systemic fungal infections in liver transplant recipients. Abstract 1650, ICAAC, September 1999.

    Google Scholar 

  83. Munoz P, Palomo J, Ya-Ez J, et al Primary prophylaxis with Itraconazole of invasive Aspergillosis in heart transplant patients. Abstract 1416, ICAAC, September 1999.

    Google Scholar 

  84. Reichenspumer H, Gamberg P, Nitschke M. et al Significant reduction in the number of fungal infections after lung-heart-lung, and heart transplantation using aerolized Amphotericin B prophylaxis. Transplantion Proceedings 1997; 29: 627–628.

    Article  Google Scholar 

  85. Calvo V, Borro J. M, Morales P. Et al Antifungal prophylaxis during the early postoperative period of lung transplantation. Chest 1999; 115:1301–1304.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sweden Department of Transplantation Surgery,Karolinska, Institute, Huddinge University hospital, Stockholom, 14186

    Jan Tollemar

Authors
  1. Jan Tollemar
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Infectious Diseases Section, Veterans Affairs Medical Center, Pittsburgh, Pennsylvania, USA

    Nina Singh M.D.

  2. Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

    Nina Singh M.D.

  3. Infectious Diseases Unit, Department of Microbiology, Hospital “12 de Octubre”, Av de Andalucia km 5,400, Madrid, E-28041, Spain

    José M. Aguado M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Tollemar, J. (2001). Antifungal prophylaxis and therapy: controversies and emerging issues. In: Singh, N., Aguado, J.M. (eds) Infectious Complications in Transplant Recipients. Perspectives on Critical Care Infectious Diseases, vol 1. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1403-9_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-1403-9_12

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5536-6

  • Online ISBN: 978-1-4615-1403-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation